The UK and EU pharmaceutical industry are today jointly asking the UK Government and the European Commission to prioritise medicines in trade talks.
The Department of Health and Social Care has published its National Genomic Healthcare Strategy, which sets out their aim to cement the UK as a global leader in genomics.
“Pharmaceutical companies have done everything in their power to prepare for a ‘no deal’ Brexit. This includes increasing stocks of medicines, changing and adding new supply routes and duplicating manufacturing processes here and in Europe."
The UK and Japan have reached an agreement on the terms of a future trade deal. This will allow pharmaceutical companies in the UK to continue trading largely as they do now come 1 January 2021.
The MHRA has published information for pharmaceutical companies preparing for the end of the Brexit transition period.
The Health Secretary has announced that Public Health England is to be replaced with a new body called the National Institute for Health Protection, in a merger of the pandemic response work of PHE and NHS Test and Trace.
The UK has published additional information related to the operation of the Northern Ireland Protocol in a new policy paper, Moving goods under the Northern Ireland Protocol.
The DHSC has published a letter setting out the government’s plan and requests of industry and the wider supply chain ahead of the end of the Brexit transition period to help ensure the continuity of supply of medical goods into and out of the UK.
In his speech, the Chancellor Rishi Sunak outlined important short-term measures to support businesses hit by the coronavirus pandemic.
More than 20 leading biopharmaceutical companies announced the launch of the AMR Action Fund, a ground-breaking partnership that aims to bring 2-4 new antibiotics to patients by 2030.